Dabrafenib Mesylate

SKU: orb1298903

Description

Dabrafenib Mesylate is a potent and selective B-Raf inhibitor, with IC50 values of 0.6 nM for RafV600E and 5.0 nM for c-Raf. It is widely used in preclinical research to investigate targeted therapies for BRAF-mutant cancers in both cellular assays and animal models.

Research Area

Pharmacology & Drug Discovery, Signal Transduction

Key Properties

• CAS Number: 1195768-06-9
• MW: 615.67
• Purity: 99.45% (May vary between batches)
• Formula: C₂₄H₂₄F₃N₅O₅S₃
• SMILES: CS(O)(=O)=O.CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F
• Target: Raf
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (5.36 mM);DMSO:85 mg/mL (138.06 mM)

Bioactivity

• Target IC50:
  B-Raf (V600E):0.6 nM|Raf:5 nM
• In Vitro:
  In human endothelial cells, Dabrafenib inhibits the release of HMGB1 and down-regulates the HMGB1-dependent inflammatory response by enhancing the expression of cell adhesion molecules (CAM)

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Raf kinases, Raf, Dabrafenib, Dabrafenib Mesylate, GSK 2118436, GSK 2118436 Mesylate, GSK 2118436B, GSK2118436, GSK-2118436, GSK2118436 Mesylate, GSK-2118436 Mesylate, Inhibitor, inhibit

Compound Identifiers

PubChem CID

44516822